{"id":3455,"date":"2018-10-18T17:52:17","date_gmt":"2018-10-18T12:22:17","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3455"},"modified":"2021-07-24T12:57:06","modified_gmt":"2021-07-24T07:27:06","slug":"the-business-cocktail-41","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41","title":{"rendered":"Novartis signs; Sosei passes; Amgen remunerates; J&#038;J remunerates for RSV drug"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Novartis signs USD 2.1Billion for Endocyte acquisition<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Novartis<\/strong> has\u00a0inked\u00a0<strong>USD 2.1 billion<\/strong> agreement to takeover <strong>Endocyte<\/strong>. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis\u2019 eye for <strong>USD 12 million<\/strong>. Endocyte was in the stagnation when it held its recovery hopes from earlier clinical setbacks on radioligand therapeutic <strong>177Lu-PSMA-617<\/strong>. The radioconjugated<strong> PSMA antagonist<\/strong> is a promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/vasopressin-v2-receptor-v2r-agonist-pipeline-insight\">antagonist <\/a>in an open-label, single-arm prostate cancer trial, however, its owner, <strong>ABX<\/strong>, made a deal of <strong>USD 12 million upfront<\/strong>. That has proven to be a remarkably good agreement.<\/p>\n<p style=\"text-align: justify;\"><strong>Sosei passes on buyout option after an investment of USD 45.2 million into MiNA Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Sosei<\/strong> invested <strong>USD 45.2 million<\/strong> in <strong>MiNA Therapeutics<\/strong> to acquire the RNA biotech if everything went well. The Tokyo-based company is passing on buyout option, relinquishing the right to takeover MiNA in the future. The buyout clause was related to the advancement of <strong>MTL-CEBPA<\/strong>, the lead asset of MiNA, a small activating RNA candidate that is in phase 1 for advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/liver-cancer-market\">liver cancer<\/a>.<\/p>\n<p style=\"text-align: justify;\"><strong>Amgen remunerates USD 66 Million stakes in Oxford Nanopore<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Amgen<\/strong> has invested <strong>USD 66 million<\/strong> into portable genome sequencer developer, <strong>Oxford Nanopore<\/strong>, U.K.-based company. The American multinational biopharmaceutical company expects the investment that it will go with its efforts in using genomics. <strong>deCode Genetics<\/strong> has used Oxford Nanopore devices to sequence several hundred human genomes, as well as to help identify and validate new targets.<\/p>\n<p style=\"text-align: justify;\"><strong>Johnson &amp; Johnson remunerates USD 630 Million for RSV drug\u00a0<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Johnson &amp; Johnson<\/strong> remunerated <strong>USD 1.75 billion<\/strong> to acquire antiviral specialist <strong>Alios<\/strong>, but the lead drug from that agreement now seems to be in trouble. J&amp;J disclosed that <strong>phase 2b trials<\/strong> of <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-epidemiology-forecast\">respiratory syncytial virus<\/a> (RSV) drug lumicitabine\u2014also known as <strong>AL-8176<\/strong>\u2014had been on hold, and now, in an SEC filing, it has taken a <strong>USD 630 million<\/strong>\u00a0charge for impairment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has\u00a0inked\u00a0USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis\u2019 eye for USD 12 million. Endocyte was in the stagnation when it held its recovery hopes from earlier clinical setbacks on radioligand therapeutic 177Lu-PSMA-617. The radioconjugated [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3458,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2000,2002,2011,2008,831,2007,1069,341,2004,2005,423,2006,2001,2009,2010,2003],"industry":[17225],"therapeutic_areas":[17235,17231,17557,17228,17243],"class_list":["post-3455","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-177lu-psma-617","tag-abx","tag-al-8176","tag-alios","tag-amgen","tag-decode-genetics","tag-endocyte","tag-johnson-johnson","tag-mina-therapeutics","tag-mtl-cebpa","tag-novartis","tag-oxford-nanopore","tag-radioconjugated-psma-antagonist","tag-respiratory-syncytial-virus-rsv","tag-rsv","tag-sosei","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-infectious-diseases","therapeutic_areas-male-health","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novartis signs; Sosei passes; Amgen remunerates; J&amp;J remunerates<\/title>\n<meta name=\"description\" content=\"Novartis has\u00a0inked\u00a0USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana......\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis signs; Sosei passes; Amgen remunerates; J&amp;J remunerates\" \/>\n<meta property=\"og:description\" content=\"Novartis has\u00a0inked\u00a0USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana......\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-18T12:22:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1875\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates","description":"Novartis has\u00a0inked\u00a0USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana......","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41","og_locale":"en_US","og_type":"article","og_title":"Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates","og_description":"Novartis has\u00a0inked\u00a0USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana......","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-10-18T12:22:17+00:00","article_modified_time":"2021-07-24T07:27:06+00:00","og_image":[{"width":3000,"height":1875,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41","name":"Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","datePublished":"2018-10-18T12:22:17+00:00","dateModified":"2021-07-24T07:27:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Novartis has\u00a0inked\u00a0USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana......","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-41#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","width":"3000","height":"1875","caption":"100 dollar bills, pills, and medicine containers"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma-300x188.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">177Lu-PSMA-617<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ABX<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AL-8176<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alios<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">deCode Genetics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Endocyte<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson &amp; Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MiNA Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MTL-CEBPA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Oxford Nanopore<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">radioconjugated PSMA antagonist<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">respiratory syncytial virus (RSV)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RSV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sosei<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">177Lu-PSMA-617<\/span>","<span class=\"advgb-post-tax-term\">ABX<\/span>","<span class=\"advgb-post-tax-term\">AL-8176<\/span>","<span class=\"advgb-post-tax-term\">Alios<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">deCode Genetics<\/span>","<span class=\"advgb-post-tax-term\">Endocyte<\/span>","<span class=\"advgb-post-tax-term\">Johnson &amp; Johnson<\/span>","<span class=\"advgb-post-tax-term\">MiNA Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">MTL-CEBPA<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Oxford Nanopore<\/span>","<span class=\"advgb-post-tax-term\">radioconjugated PSMA antagonist<\/span>","<span class=\"advgb-post-tax-term\">respiratory syncytial virus (RSV)<\/span>","<span class=\"advgb-post-tax-term\">RSV<\/span>","<span class=\"advgb-post-tax-term\">Sosei<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 18, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 18, 2018 5:52 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"100 dollar bills, pills, and medicine containers","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3455"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3458"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3455"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3455"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}